Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 77

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 77
---
/or omits material information concerning the transaction. Although no such lawsuits have yet been filed in connection with the Business Combination, it is possible that such actions may arise and, if such actions do arise, they generally seek, among other things, injunctive relief and an award of attorneys’ fees and expenses. Defending such lawsuits could require Longevity and FutureTech to incur significant costs and draw the attention of Longevity’s and FutureTech’s management teams away from the consummation of the Business Combination. Further, the defense or settlement of any lawsuit or claim that remains unresolved at the time the Business Combination is consummated may adversely affect the combined company’s business, financial condition, results of operations and cash flows. Such legal proceedings could delay or prevent the Business Combination from being consummated within the expected timeframe.

The announcement of the proposed Business Combination could disrupt Longevity’s and the Targets’ relationships with its suppliers, business partners and others, as well as its operating results and business generally.

Risks relating to the impact of the announcement of the Business Combination on Longevity’s and the Targets’ businesses include the following:

| ● | its                                                                                         
 employees may experience uncertainty about their future roles, which might adversely affect 
 Longevity’s ability to retain and hire key personnel and other employees;                   |

| ● | suppliers,                                                                                     
 business partners and other parties with which Longevity and the Targets maintain business     
 relationships may experience uncertainty about their future and seek alternative relationships 
 with third parties, seek to alter their business relationships with Longevity or the Targets   
 or fail to extend an existing relationship with Longevity or the Targets; and                  |

| ● | Longevity                                                                                      
 has expended and will continue to expend significant costs, fees and expenses for professional 
 services and transaction costs in connection with the proposed Business Combination.           |

| 25 |

If any of the aforementioned risks were to materialize, they could lead to significant costs which may impact the combined company’s results of operations and cash available to fund its business.

Subsequent to consummation of the Business Combination, we may be exposed to unknown or contingent liabilities and may be required to subsequently take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and our share price, which could cause you to lose some or all of your investment.

We cannot assure you that the due diligence conducted in relation to Longevity has identified all material issues or risks associated with Longevity or the industry in which it compet